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Abstract
Neurofibromatosis type 1 (NF1) predisposes individuals to early and debilitating cardiovascular 
disease. Loss of function mutations in the NF1 tumor suppressor gene, which encodes the protein 
neurofibromin, leads to accelerated p21Ras activity and phosphorylation of multiple downstream 
kinases, including Erk and Akt. Nf1 heterozygous (Nf1+/−) mice develop a robust neointima that 
mimics human disease. Monocytes/macrophages play a central role in NF1 arterial stenosis as Nf1 
mutations in myeloid cells alone are sufficient to reproduce the enhanced neointima observed in 
Nf1+/− mice. Though the molecular mechanisms underlying NF1 arterial stenosis remain elusive, 
macrophages are important producers of reactive oxygen species (ROS) and Ras activity directly 
regulates ROS production. Here, we use compound mutant and lineage-restricted mice to 
demonstrate that Nf1+/− macrophages produce excessive ROS, which enhance Nf1+/− smooth 
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muscle cell proliferation in vitro and in vivo. Further, use of a specific NADPH oxidase-2 inhibitor 
to limit ROS production prevents neointima formation in Nf1+/− mice. Finally, mononuclear cells 
from asymptomatic NF1 patients have increased oxidative DNA damage, an indicator of chronic 
exposure to oxidative stress. These data provide genetic and pharmacologic evidence that 
excessive exposure to oxidant species underlie NF1 arterial stenosis and provide a platform for 
designing novels therapies and interventions.
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1. Introduction
Neurofibromatosis type 1 (NF1) is a common genetic disorder resulting from germline 
mutations in the NF1 tumor suppressor gene and affects over 2 million people worldwide 
[1]. Neurofibromin, the protein product of NF1, functions as a catalyst for the slow, intrinsic 
hydrolysis of active p21Ras (Ras) [1]. Thus, loss of neurofibromin expression increases Ras-
dependent kinase activity in response to growth factor stimulation of receptor tyrosine 
kinases. The downstream Ras kinases Erk and Akt turn on multiple molecular switches to 
promote a pro-survival phenotype in neurofibromin-deficient cells.
Persons with NF1 have a strong predisposition for cardiovascular disease, which often 
presents in adolescence and early adulthood [2–4]. Upwards of 8% of NF1 patients will 
develop hypertension, arterial stenosis, aortic aneurysms, or moyamoya, though universal 
screening has not been adopted and may underestimate the true prevalence of disease [4–6]. 
The distribution of NF1 vasculopathy within a single patient is often patchy and affects 
multiple vessels [4]. The varied presentation of arterial lesions suggests that NF1 patients 
may require a “second hit” mutation in the normal NF1 allele or, more likely, a local insult 
in the vessel wall leading to dysregulation of normal repair mechanisms. Constitutional 
homozygosity for NF1 mutations is embryonic lethal in humans and mice; therefore, 
inherited mutations in a single NF1 allele are likely sufficient for the increased disease 
prevalence and provide a platform for investigation [7].
We have developed a mouse model of NF1 arterial stenosis using Nf1 heterozygous (Nf1+/−) 
mice that phenotypically resembles human NF1 arterial lesions [8–12]. Following carotid 
artery injury, Nf1+/− mice develop a robust neointima when compared with WT mice, which 
is characterized by α-SMA positive smooth muscle cells (SMC) and a predominance of 
bone marrow-derived macrophages within the neointima [10–12]. Disruption of PDGF-Ras-
Erk signaling inhibits Nf1+/− SMC proliferation and prevents neointima formation in Nf1+/− 
mice[9]; however, SMC-specific Nf1 heterozygosity failed to replicate the enhanced 
neointima observed in Nf1+/− mice and provides evidence that other cell populations are 
required to initiate neointima formation in Nf1+/− mice [8,10]. In support of this hypothesis, 
WT mice reconstituted with Nf1+/− bone marrow developed a pronounced neointima 
following carotid artery ligation while Nf1+/− mice reconstituted with WT bone marrow 
developed a modest neointima similar in size to WT lesions [8]. Further, we recently showed 
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that loss of a single Nf1 gene copy in myeloid cells is sufficient to reproduce the 
exaggerated arterial lesions observed in Nf1+/− mice [11]. These experiments in lineage-
restricted and chimeric mice provide strong evidence that neurofibromin-deficient 
monocytes and macrophages are critical mediators of Nf1+/− arterial stenosis. However, the 
mechanisms through which Nf1+/− monocytes and macrophages directly influence Nf1+/− 
SMC proliferation and arterial stenosis is completely unknown.
Emerging evidence suggests that Ras kinases directly regulate reactive oxygen species 
(ROS) production and, in turn, ROS may modulate Ras activity [13–15]. Constitutive 
activation of Ras in hematopoietic progenitor and cancer cells dramatically increases ROS 
production via activation of the NADPH oxidase complex [16–19]. Also, Drosophila 
harboring mutations in the Nf1 gene exhibited shortened lifespan and increased production 
of and vulnerability to ROS [20,21], while overexpression of neurofibromin prolonged 
lifespan and reduced ROS production [22]. More recently, neurofibromin deficiency or Ras 
activation significantly increased oligodendrocyte ROS production and disrupted endothelial 
tight junctions, which was restored by daily administration of the antioxidant N-acetyl 
cysteine [23]. These findings are intriguing since neurofibromin occupies a unique position 
in the regulation of kinases that activate ROS production and enhance SMC proliferation 
[24–26]. For example, the Ras-dependent kinases Akt and Erk directly phosphorylate the 
p47phox subunit of NADPH oxidase 2 (NOX2) and facilitate Rac2-dependent recruitment of 
p67phox to the transmembrane component of NOX2 to increase superoxide production in 
phagocytes [27–29]. Overproduction of ROS in infiltrating leukocytes via NOX2 therefore 
may augment SMC function and participate in the pathogenesis of arterial lesions in NF1 
patients. Therefore, we hypothesize that loss of neurofibromin in monocytes/macrophages 
enhances ROS production via NOX2 activation and amplifies Nf1+/− SMC proliferation 
leading to occlusive arterial disease. As a corollary to our experimental murine work, we 
seek to identify whether NF1 patients experience chronic oxidative stress.
2. Materials and methods
2.1. Animals
Protocols were approved by Laboratory Animal Services at Augusta University and Indiana 
University. Nf1+/− mice were obtained from Tyler Jacks (Massachusetts Institute of 
Technology, Cambridge, MA) and backcrossed 13 generations into the C57BL/6J strain. 
p47phox (4742) knockout mice (p47−/−) were purchased from The Jackson Laboratory and 
maintained on C57BL/6 strain. Nf1+/−mice were intercrossed with p47−/− mice to produce 
Nf1+/−;p47−/−mice. Nf1flox/flox mice were obtained from Luis Parada (University of Texas 
Southwestern Medical Center, Dallas, TX) and maintained on C57BL/6 background. 
gp91flox/flox mice were obtained from Abay Shah (King’s College, London, UK). LysMcre 
(4781) mice were purchased from The Jackson Laboratory and maintained on C57BL/ 6 
background. Nf1flox/flox mice were crossed with gp91flox/flox and LysMcre mice to generate 
Nfflox/+;gp91flox/flox;LysMcre mice (heterozygous loss of Nf1 and homozygous loss of 
gp91phox in myeloid cells only). LysM is expressed in neutrophils and macrophages. Cre-
mediated recombination was confirmed by PCR as previously described [11]. Inbreeding of 
Nf1flox/flox mice with LysMcre mice yielded Nf1flox/+;LysMcre (heterozygous loss of Nf1 in 
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myeloid cells alone) and Nf1flox/+ (WT) controls. Male mice, between 12 and 15 weeks of 
age, were used for experiments.
2.2. Carotid artery ligation
Carotid artery injury was induced by ligation of the right common carotid artery as 
previously described [11]. Briefly, mice were anesthetized by inhalation of an isoflurane 
(2%)/oxygen (98%) mixture. Under a dissecting scope, the right carotid artery was exposed 
through a midline neck incision and ligated proximal to the bifurcation using a 6-0 silk 
suture. The contralateral carotid artery was sham ligated as a control. Mice were 
administered 15 μg of buprenorphine (IP) following the procedure and recovered for 28 
days. Whole ligated and control arteries were harvested from experimental mice for analysis 
as previously described.
2.3. Morphometric analysis
Van Gieson-stained arterial cross Sections 400, 800, and 1200 μm proximal to the ligation 
were analyzed for neointima formation using Image J (NIH, Bethesda, MD). Lumen area, 
area inside the internal elastic lamina (IEL), and area inside the external elastic lamina 
(EEL) were measured for each cross section. To account for potential thrombus formation, 
arteries containing significant thrombus (>50% lumen occlusion) at 400 μm proximal to the 
ligation were excluded from analysis. The number of excluded arteries was not different 
between experimental groups. Representative photomicrographs for each figure are taken 
from arterial cross sections between 600 and 1200 μm proximal to the bifurcation. Intima 
area was calculated by subtracting the lumen area from the IEL area, and the media area was 
calculated by subtracting the IEL area from the EEL area. Intima/media (I/M) ratio was 
calculated as intima area divided by media area.
2.4. Arterial ROS detection in vivo
Carotid arteries from Nf1+/− and WT mice were injured as described above. Forty-eight 
hours after injury, dihydroethidium (20 mg/kg) was provided via IP injection. After an 
additional 24-h recovery period, mice were sacrificed and whole control and injured carotid 
arteries were perfused with heparinized saline and flash frozen in OCT compound. Arterial 
cross sections (20 μm) were analyzed for fluorescence using an EVOS FL microscope. In a 
second set of experiments, whole arteries from Nf1+/− and WT mice were harvested 72 h 
after injury and pooled, minced into a single cell suspension, and placed in boiling sodium 
dodecyl sulfate (SDS) buffer. NOX2 and β-actin expression were analyzed by western blot.
2.5. Isolation of bone marrow-derived macrophages, characterization, and ROS 
determination
Bone marrow-derived macrophage isolation and characterization was performed as 
described [8]. To assess ROS production, WT, Nf1flox/+;LysMcre, and Nf1flox/flox;LysMcre 
macrophages (5 × 105 cells) were suspended in 0.5 mL Hank’s Balanced Salt Solution 
(HBSSS) and stimulated with 100 nM phorbol myristate acid (PMA). L-012 (2 μM) with 
and without 50 units/mL superoxide dismutase (SOD) was added to the suspension and 
luminescence was measured at 15-s intervals in a luminometer. In some experiments, 
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macrophages were incubated with PD0325901 (10 nM) or wortmannin (50 nM) to 
specifically inhibit Erk and Akt activity, respectively. All experiments were performed in 
triplicate in four distinct cohorts.
2.6. Smooth muscle cell isolation and proliferation
Smooth muscle cell isolation and proliferation assays were performed as described [26]. 
SMC were obtained by outgrowth from explants of WT and Nf1+/− thoracic aortas. SMC 
were cultured in DMEM supplemented with 20% fetal bovine serum and 100 U/ml 
penicillin/streptomycin in a 37 °C, 5% CO2-humidified incubator. For cell proliferation, 
SMC (5000 cells/cm2) were placed in a 96-well plate and deprived of growth factors for 12–
18 h. Quiescent SMC were stimulated with H2O2 (1 and 100 μM) for 24 h and pulse-labeled 
with 1 μCi/ml of [3H] thymidine for 6 h. β emission was measured and reported as counts 
per minute. Cell counts using a hemocytometer were performed to confirm radioisotope 
results. Under the same conditions, cell viability was assessed by MTT assay and light 
absorbance was measured using a plate reader (570 nm). All experiments were performed in 
triplicate in four distinct cohorts.
2.7. Patient recruitment
NF1 patients were recruited by the Indiana University NF1 Clinic at Riley Hospital for 
Children. All patients received a physical examination and a medical history was taken to 
confirm the diagnosis of NF1 according to the NIH clinical criteria [30]. Patients with a 
history of cancer, on anti-cancer drugs or pregnant were excluded from the study. All 
patients gave informed consent prior to participation in the study.
2.8. Isolation of human peripheral blood mononuclear cells and analysis
Blood samples were collected from NF1 patients (37.6±9.7 years) and age- and sex-matched 
healthy controls (40.2±8.1 years) into EDTA Vacutainer tubes (BD Biosciences). Peripheral 
blood mononuclear cells (MNCs) were isolated from 16 ml of peripheral blood by density 
centrifugation using Ficoll-Paque Plus (GE Healthcare) as previously described [31]. A total 
of 1 × 106 MNCs were resuspended in PBS with 2% FBS and incubated with human FcR 
Blocking Reagent (Miltenyi Biotec) for 10 min at 4 °C. After blocking, MNCs were 
incubated for 30 min at 4 °C with the following primary conjugated monoclonal antibodies: 
anti–human CD14–PECy5.5 (Abcam), anti–human CD45–allophycocyanin–Alexa Fluor 
750 (Invitrogen), and anti-human CD16–PECy7 (BD Biosciences — Pharmingen), as well 
as the live/dead marker ViVid (Invitrogen). After staining, MNCs were washed 2 times with 
PBS with 2% FBS and fixed in 1% formaldehyde (Sigma-Aldrich) for a minimum of 24 h. 
Stained MNC samples were acquired on a BD LSRII flow cytometer equipped with a 405-
nm violet laser, 488-nm blue laser, and 633-nm red laser. At least 300,000 events were 
collected for each sample. Data were collected uncompensated and analyzed using FlowJo 
software version 8.7.3 (Tree Star).
2.9. Modified comet assay in human mononuclear cells
MNCs were assayed for oxidative DNA damage as previously described, with modification 
[32]. Following cell lysis, slides were treated with formamidopyrimidine DNA glycosylase 
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(FPG), which recognized and removed oxidized purines, causing a DNA break. For each 
sample, 100 cells were analyzed. The Institutional Review Board of the Indiana University 
School of Medicine approved all protocols using human tissue samples.
2.10. Statistics
All values are presented as mean±S.E.M. unless otherwise noted. Human monocyte 
frequency and leukocyte oxidative-DNA damage was analyzed using Student’s t-test and 
sample distribution was analyzed by F-test. Macrophage ROS production and SMC 
proliferation and viability was analyzed using 2-way ANOVA with Tukey’s post-hoc test for 
multiple comparisons. Intima area and I/ M ratio analysis was assessed by 1-way ANOVA 
with Tukey’s post-hoc test for multiple comparisons. Murine experiments using apocynin 
treatment were assessed using 2-way ANOVA with Tukey’s post-hoc test for multiple 
comparisons. Analysis was performed using GraphPad Prism version 5.0 d. P<0.05 were 
considered significant.
3. Results
3.1. Neurofibromin-deficient macrophages produce excessive super-oxide via p21Ras 
activation
The p21Ras pathway directly, but not completely, regulates intracellular and extracellular 
oxidant species concentration; therefore, Ras activation in neurofibromin-deficient 
leukocytes may increase ROS production. To examine the role of neurofibromin-deficiency 
in leukocyte-mediated ROS production, we utilized cre/ lox technology to isolate Nf1 
heterozygous and homozygous macrophages. As Nf1 nulzygosity results in embryonic 
lethality, we isolated bone marrow macrophages from Nf1flox/+;LysMcre (Nf1 heterozygous 
in myeloid cells) and Nf1flox/flox;LysMcre (Nf1 homozygous in myeloid cells) and subjected 
them to stimulation with phorbol myristate acetate (PMA) to provoke ROS production. In 
response to PMA stimulation, neurofibromin-deficient macrophages generated greater 
quantities of ROS when compared to WT macrophages (Fig. 1). In fact, a gene-dosage 
response was observed in neurofibromin-deficient macrophages (Fig. 1A and B). The 
addition of superoxide dismutase (SOD) effectively quenched ROS production, indicating 
that Nf1 mutant macrophages produce excessive superoxide primarily (Fig. 1B).
To examine whether Ras activation in neurofibromin-deficient macrophages directly 
regulates ROS production, we elicited ROS production in WT and Nf1+/− macrophages with 
PMA in the presence of PD0325901, an inhibitor of Ras-Mek-Erk, and wortmannin, an 
inhibitor of Ras-PI-3K. In response to PMA, Nf1+/− macrophages produced significantly 
more ROS when compared with WT macrophages and this response was completely 
inhibited in the presence of either Erk or Akt inhibitors (Fig. 1C). WT macrophages also 
produced little ROS when co-incubated with PD0325901 or wortmannin, which suggests 
that PMA likely induces ROS production via Ras activation.
3.2. Nf1+/− SMC are sensitive to oxidative stress
Reactive oxygen species modify the response of intracellular signaling pathways, including 
p21Ras, and may exaggerate the response of extracellular growth signals to induce cell 
Bessler et al. Page 6
Free Radic Biol Med. Author manuscript; available in PMC 2018 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
proliferation and survival. More specifically, superoxide and its primary by-product 
hydrogen peroxide (H2O2) are important mitogens for SMC [33–36]. Based on the 
observation that neurofibromin-deficient macrophages produce excessive ROS, we isolated 
SMC from the aortas of WT and Nf1+/− mice to interrogate the potential paracrine effects of 
local ROS production by infiltrating Nf1+/−macrophages on arterial SMC in vitro. Under 
growth-restrictive conditions, Nf1+/− SMC exhibit increased proliferation when compared 
with WT SMC [11,12,26]. To account for this inherent advantage, we compared quiescent 
Nf1+/− and WT SMC incubated with/without H2O2 to mimic exposure to vascular oxidative 
stress. In response to low micromolar concentrations of H2O2, Nf1 +/− SMC exhibited a 
dose-responsive increase in thymidine incorporation, while higher concentrations of H2O2 
failed to stimulate Nf1 +/− SMC proliferation (Fig. 2A). Thymidine incorporation was also 
dose-responsive in WT SMC, though higher H2O2 concentrations were required to induce 
the same proliferative response and statistical significance was not achieved. Interestingly, 
WT and Nf1+/− SMC viability dropped significantly in response to stimulation with 100 μM 
H2O2 as determined by MTT assay (Fig. 2B). Both low and high concentrations of H2O2 
preferentially activated Erk in Nf1 +/− SMC when compared to WT SMC, while Ras-PI-3K 
activity remained largely unchanged (Fig. 2C). Consistent with decreased cell viability, 
incubation of Nf1+/− SMC with 100 μM H2O2 induced the cleavage of caspase-3, an 
indicator of apoptosis (Fig. 2C). These data suggest that low-level ROS amplifies Erk 
activity in Nf1+/−SMC and potentiates Nf1+/− SMC proliferation, while higher 
concentrations of H2O2 may induce Nf1 +/− SMC apoptosis. The latter is an important 
observation since SMC apoptosis is a critical step in the development of aortic aneurysms, 
which is a less common manifestation of NF1 vasculopathy [2,37]. Additionally, we 
examined Nf1+/− and WT SMC for native ROS production in response to incubation with 
H2O2 to identify particular advantages that neurofibromin-deficiency and/or Ras activation 
might have on ROS production. Quiescent Nf1+/− and WT SMC exhibited similar basal ROS 
production and the addition of H2O2 (10 and 100 μM) did not confer additional ROS 
production in Nf1+/− SMC when compared with WT SMC (data not shown). Thus, it is 
unlikely that Nf1+/−SMC produce sufficient quantities of ROS to autonomously induce SMC 
proliferation and arterial stenosis de novo, but may confer an additive effect to local ROS 
production by infiltrating macrophages.
3.3. NOX2 expression is upregulated in Nf1+/− carotid arteries
Previously, we showed that Nf1+/− mice develop exaggerated neointimas and excessive 
remodeling when compared with WT mice, which is largely mediated by neurofibromin-
deficient monocytes/macrophages [9,11]. While loss of neurofibromin expression leads to 
increase Ras signaling and enhances macrophage survival and function, the inciting 
mechanism(s) leading to rampant SMC proliferation and neointima formation are poorly 
understood. To examine the potential role of excessive ROS production by Nf1+/− 
macrophages on the vascular wall, we harvested control and ligated arteries from Nf1+/− and 
WT mice 3 days after injury. Prior to tissue harvest, animals were provided dihydroethidium 
(DHE) via IP injection to detect ROS in the vascular wall. In comparison to control vessels, 
injured arteries from both genotypes exhibited increase DHE staining indicating an 
upregulation in ROS production (Fig. 3A). However, injured Nf1+/− arteries showed only a 
modest increase in ROS expression compared to injured WT arteries at this early time point. 
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Next, control and injured carotid arteries from Nf1+/− and WT mice were pooled and 
analyzed for NOX2 expression. Interestingly, control Nf1+/− arteries have increased 
expression of NOX2 compared to WT control arteries (Fig. 3B). In response to arterial 
ligation, both WT and Nf1+/− carotid arteries have enhanced expression of NOX2 compared 
to genotype-specific controls, though injured Nf1+/− arteries exhibited the highest NOX2 
expression of all conditions tested. Although examination of an early time point after arterial 
injury did not detect significant differences in ROS production in the vessel wall between 
Nf1+/− and WT arteries, NOX2 expression in whole artery lysates suggest that 
neurofibromin regulates the expression of NOX2 and NOX2 expression is increased during 
early inward arterial remodeling.
3.4. NOX2 activation is required for Nf1+/− neointima formation
Excessive ROS production by infiltrating leukocytes in the vascular wall contributes to SMC 
proliferation and arterial stenosis [34,38] and therapeutic attempts to scavenge excess ROS 
or interrupt ROS production have proven efficacious in preclinical models of neointima 
formation [39]. Superoxide production in leukocytes is largely mediated via NADPH 
oxidase 2 (NOX2), which is activated, in part, by the Ras-dependent kinases Erk and Akt 
[17,28,40]. Based on our observation that neurofibromin-deficient macrophages produce 
excessive superoxide and Nf1+/− SMC proliferation is dose-responsive to ROS species, we 
intercrossed Nf1+/− mice with p47phox knockout mice to understand the role of NOX2 
activation in Nf1+/−neointima formation. In response to carotid artery ligation, Nf1+/− mice 
developed an enhanced neointima, which was phenotypically and histologically similar to 
our previous observations (Fig. 4). Genetic deletion of p47phox, a cytosolic component of 
NOX2 that is required for NOX2 activation, reduced neointima formation in Nf1+/− mice to 
levels observed in the background strain. Quantitative analysis of arterial cross sections from 
each cohort demonstrated a 65% reduction in neointima area and 80% reduction in intima/
media (I/M) ratio (Fig. 4B and C). Thus, p47phox expression is required for Nf1+/− neointima 
formation and NOX2 activation may be mechanistically responsible for the enhanced ROS 
production observed in Nf1 mutant macrophages.
Previously, we utilized LysMcre mice to demonstrate that loss of a single Nf1 gene copy in 
monocytes/macrophages is sufficient to reproduce the enhanced neointima observed in 
neurofibromin-deficient mice [11]. In order to specifically interrogate the role of 
macrophage-specific ROS production in the pathogenesis of Nf1 arterial stenosis, we 
intercrossed Nf1flox/+;LysMcre mice with gp91flox/flox mice to generate 
Nf1flox/+;gp91flox/flox;LysMcre mice with specific deletion of both gp91phox alleles in Nf1+/− 
monocytes and macrophages. gp91phox is the glycosylated membrane-bound component of 
NOX2 and is required for electron transfer to molecular oxygen in the generation of 
superoxide [41]. Cre+ and Cre− mice were subjected to carotid artery ligation to induce 
neointima formation. Lineage-restricted inactivation of a single Nf1 allele in myeloid cells 
alone was sufficient to induce a robust neointima that is an exact phenocopy of neointimas 
observed in Nf1+/− mice after arterial injury (Fig. 5). In contrast, genetic deletion of both 
gp91phox alleles in Nf1flox/+;LysMcre mice resulted in a 75% reduction in neointima 
formation after arterial injury when compared to Nf1flox/+;LysMcre mice (Fig. 5B and C). 
Collectively, these data provide genetic evidence that the presence and activation of NOX2 is 
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necessary for Nf1+/− neointima formation and limiting ROS production may be a viable 
therapeutic target for the prevention and/or treatment of NF1 arterial stenosis.
3.5. Apocynin inhibits neointima formation in Nf1+/− mice
The proximity of invading Nf1+/− macrophages to vascular wall SMC and their propensity 
for superoxide production may be pathologically linked to neointima formation in Nf1+/− 
mice. Sequestering ROS production provides an attractive therapeutic option since anti-
oxidants are well tolerated and may be particularly effective in NF1 patients with evidence 
of oxidative stress. The antioxidant apocynin is intriguing since it binds the p47 subunit in 
the cytosol and interferes with NOX2 activation [42–44]. Therefore, we subjected Nf1+/− 
and WT mice to carotid artery ligation to induce arterial stenosis and provided drinking 
water containing or lacking apocynin (100 mg/kg/day) for 28 days until the arteries were 
harvested and analyzed for neointima formation. In response to carotid artery injury, WT 
mice developed a modest neointima while Nf1+/− mice developed a severe arterial stenosis, 
which was similar to our previous observations (Fig. 6). In contrast, daily administration of 
apocynin reduced Nf1+/− neointima area and I/M ratio by 75% in comparison with control 
Nf1+/− mice (Fig. 6A and B). WT mice experienced a modest, but non-significant reduction 
in neointima formation, which is likely due to their resistance to neointima formation.
3.6. NF1 patients have increased pro-inflammatory monocytes and evidence of chronic 
oxidative stress
Loss of Nf1 may increase the susceptibility of whole organisms and primary cells to 
oxidative stress, and previous studies have suggested interplay between chronic oxidative 
stress and inflammation in tissue derived from NF1 patients. However, evidence of oxidative 
stress has not been demonstrated in persons with NF1 [8,45–47]. Therefore, we isolated 
peripheral blood MNCs to examine them for evidence of oxidative stress. In comparison 
with age- and sex-matched controls, total monocyte count was elevated in asymptomatic 
NF1 patients. Examination of monocyte subpopulation frequency showed that some healthy 
persons with NF1 had a substantial increase in the frequency of a monocyte subpopulation 
(CD14+CD16+ +) associated with inflammatory conditions and oxidative stress [48–50] (Fig. 
7A and B). The mean frequency of CD14+CD16+ + monocytes in the NF1 cohort was 2.5 
times higher than the mean frequency of CD14+CD16+ + monocytes in the control cohort 
(40.8±14 vs. 15.73±4.3 cells/μL, P=0.06). Within the NF1 cohort, we observed that some 
NF1 patients exhibited a significant elevation in the frequency of circulating CD14+CD16+ + 
monocytes, which may cause a positive skew in the sample distribution. To determine if the 
sample distribution in these two cohorts could occur by random chance, we performed an F-
test of variance. This secondary analysis revealed a significant difference in CD14+CD16+ + 
monocyte frequency variance between NF1 and control patients (P<0.001). Monocyte 
subpopulation frequencies must be interpreted in relationship to controls since normal values 
do not presently exist. While nearly 60% of healthy controls had a CD14+CD16+ + 
monocyte frequency of less than 10,000 cells/μL in their peripheral blood, less than 45% of 
healthy persons with NF1 met the same cutoff value. In fact, the highest CD14+CD16+ + 
monocyte frequency observed in persons with NF1 were 2–3 fold higher than the highest 
observed frequencies in control patients (Fig. 7B). In comparison, the frequency of 
patrolling or “classical” monocytes did not differ between control and NF1 patients Fig. 7C. 
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Since CD14+ +CD16− classical monocytes arise from the bone marrow and give rise to 
CD14+ +CD16+ intermediate and CD14+CD16+ + non-classical monocytes, this data 
suggests that the increased frequency of CD14+CD16+ + monocytes is the result of signaling 
inputs outside the bone marrow compartment and do not arise from alterations in 
developmental maturation [50].
Next, we examined peripheral blood MNCs for evidence of oxidative stress using a modified 
comet assay to analyze for oxidative DNA damage. Monocytes isolated from NF1 patients 
displayed a 2-fold increase in oxidative DNA damage when compared with control patients 
(Fig. 7D Thus, NF1 patients have evidence of chronic oxidative stress and inflammation, 
which may predispose them to premature and/or severe forms of cardiovascular disease.
4. Discussion
Despite a high propensity for severe forms of cardiovascular disease, tailored therapies for 
NF1 patients with vasculopathy are nonexistent. The lack of a concise therapeutic approach 
to NF1 vasculopathy is largely due to a poor understanding of disease pathogenesis and 
latency in disease presentation. To date, most therapeutic studies have targeted downstream 
Ras kinases as their activity is deregulated and amplified in persons with NF1. While Ras 
pathway inhibitors are mechanistically plausible for the treatment of cardiovascular 
manifestations in NF1 patients, long-term treatment of cardiovascular diseases with Mek-
Erk or Ras-PI-3K inhibitors is not practical due to the necessity of this highly conserved 
pathway in normal cell growth and differentiation. Thus, the need for highly efficacious and 
well-tolerated compounds for persons with NF1 vasculopathy must leverage the unique 
biochemistry found in neurofibromin-deficient tissue while maintaining a favorable side-
effect profile.
Emerging evidence suggests that oxido-reductive balance is disturbed in active Ras mutants 
and neurofibromin-deficient tissues and humans. The interaction between ROS and Ras is 
multi-faceted, but reactive oxygen and nitrogen species have been identified as upstream 
modulators and downstream targets of several Ras kinases [13]. Active Ras mutations or 
upregulation of Ras signaling leads to increased expression of NADPH oxidases to enhance 
ROS production in multiple cell types [17,51–53]. Ras activation through growth factor 
binding of various receptor tyrosine kinases may cooperate with small molecule modulators, 
such as ROS, to enhance phosphorylation of the downstream kinases Erk and Akt [54]. In 
turn, inhibition of ROS production appears to decrease Erk and Akt activity so that signaling 
feedback between ROS and Ras is critical for cell homeostasis [55–57]. The physiologic 
interaction of ROS and p21Ras may turn pathologic in the setting of neurofibromin-
deficiency as evidenced by recent studies. Oligodendrocytes containing either inactivating 
Nf1 or active HRAS mutations produce excessive ROS leading to disruption of local 
endothelial tight junctions and increased vascular permeability, which is restored with the 
administration of the antioxidant N-acetyl cysteine [23]. Neurofibromin may also express a 
more direct relationship with mitochondrial ROS production via protein kinase A (PKA). 
Mutations in the Drosophila Nf1 homolog increased mitochondrial ROS production, 
shortened lifespan, and sensitized flies to oxidative stress [22]. Over-expression of PKA 
restored a normal response to oxidative stress in Nf1 mutant Drosophila [58]. Conversely, 
Bessler et al. Page 10
Free Radic Biol Med. Author manuscript; available in PMC 2018 January 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
overexpression of neurofibromin in Drosophila provided resistance to oxidant injury and 
prolonged mean lifespan. Here, we show that superoxide production by differentiated 
macrophages is directly regulated by neurofibromin via a gene-dosage dependent 
mechanism.
In support of neurofibromin’s role in ROS production, we provide the first evidence of 
chronic oxidative stress in NF1 patients, as demonstrated by increased comet tail moment, 
an indicator of oxidative DNA damage [59]. Recent studies suggest that neurofibromin also 
regulates cell cycle and DNA repair pathways; therefore, loss of neurofibromin may prevent 
normal DNA repair to occur and may be an alternative explanation for the enhanced 
oxidative DNA damage [60]. However, measurement of direct DNA damage did not differ 
between NF1 and control patients (data not shown). Regardless, the implications of these 
findings may be broad-based since excessive ROS production and oxidative DNA damage 
may participate in several manifestations of NF1, including cancer, impaired learning and 
cognition, and musculoskeletal diseases. Further, modulating ROS production is an attractive 
therapeutic alternative for NF1 patients and may have additive effects since neurofibromin 
restrains ROS production directly and indirectly.
Monocytes and macrophages appear to play a critical role in the pathogenesis of NF1 
vasculopathy. Lineage-restricted inactivation of Nf1 in myeloid cells leads to a pro-
inflammatory monocyte profile in mice and is sufficient to recapitulate the arterial stenosis 
phenotype observed in persons with NF1 [11]. Nf1 mutant macrophages are readily 
recruited to sites of vascular injury and the excessive ROS production by Nf1+/− 
macrophages appears to promote a proliferative SMC response in vitro and in vivo. 
Interestingly, PMA elicited more ROS in Nf1 mutant macrophages as compared to WT 
macrophages, which was effectively blocked by co-incubation with inhibitors of Ras. PMA 
is a potent stimulus for NADPH via Ras-Erk dependent and independent mechanisms and 
may explain the exaggerated response of Nf1+/−and Nf1−/− macrophages to PMA [61–64]. 
Increased production of ROS may propagate a pro-survival macrophage phenotype and 
increase the generation and secretion of pro-inflammatory cytokines, although this has yet to 
be demonstrated [65]. Neurofibromin’s role in regulating monocyte/macrophage-mediated 
ROS is further emphasized by the observation that apocynin significantly inhibited 
neointima formation in Nf1+/− mice while having little effect on WT neointima formation. 
Although apocynin is generally recognized as a nonspecific antioxidant in vascular wall 
cells, Heumuller et al. concluded that apocynin dimerizes in myeloperoxidase-expressing 
cells, including macrophages, and suppresses superoxide production in leukocytes by 
inhibiting the binding of the cytosolic p47phox subunit to the transmembrane NOX2 complex 
[42]. Apocynin’s dual roles as an antioxidant and specific inhibitor of NOX2 activity likely 
contribute to the reduced neointima formation observed in Nf1+/− mice. These observations 
are supported by our findings that genetic deletion of p47phox or myeloid cell specific 
inactivation of gp91phox inhibited neointima formation in Nf1+/− mice. Further, the 
activation of p47phox is highly regulated by the Ras dependent kinases Erk and Akt, which is 
required for NOX2 activation and superoxide production in circulating phagocytes [66–68]. 
Directly targeting NOX2 for the prevention and/or treatment of NF1-related arterial stenosis 
may not be viable as NOX2 is critical for respiratory burst and phagocytosis, though clinical 
trails of small molecule NOX inhibitors are forthcoming [40].
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Antioxidants, on the other hand, have yielded promising results in multiple preclinical 
models of arterial stenosis, but human clinical trials have demonstrated only a modest effect 
[69–71]. Inhibition of ROS production or sequestering its activity via anti-oxidant therapy 
may provide a greater beneficial effect in patients with active Ras mutations, including NF1, 
than that observed in the general population since small perturbations in kinase activity 
precipitate a dramatic increase in downstream signaling. For example, anti-oxidant therapy 
significantly reduced vascular wall ROS in Nf1+/− aortas exposed to angiotensin II (AngII) 
while having minimal effect on ROS in WT aortas [72]. The preferential effect of 
antioxidant therapy in Nf1+/− mice may be explained by the high numbers of macrophages 
observed in Nf1+/− aortas exposed to AngII resulting in an abundance of oxidant species. 
Interestingly, low dose simvastatin, an HMG-CoA reductase inhibitor with anti-oxidant 
properties, effectively blocked ROS production in Nf1+/−aortas exposed to AngII with only a 
modest treatment effect observed in WT aortas exposed to AngII. While the pleiotropic 
effects of statins are widely studied, their function as an inhibitor of prenylation has made 
them an attractive therapy for NF1 patients since prenylation is required for Ras activation 
[73]. The ability of statins to modulate Ras activity and scavenge oxidative species may 
cooperate to limit the production and local concentration of ROS within the vascular wall. 
Statins have proven beneficial for a variety of NF1 manifestations including cognitive 
deficits, behavioral impairment, bone dysplasia and healing in preclinical models, but 
randomized trials in NF1 patients have yielded mixed results [11,74–77]. To date, no clinical 
trials for NF1 vasculopathy have been performed.
In summary, our study identifies a novel role for neurofibromin signaling in the generation 
of reactive oxygen species and provides genetic and pharmacologic evidence that excessive 
ROS is linked to NF1 vasculopathy. Further, we provide the first human data to suggest that 
NF1 patients experience chronic oxidative stress. As neurofibromin-deficient myeloid cells 
are critical cellular mediators of multiple manifestations of NF1, our findings provide a 
framework for interrogating ROS in NF1 biology and the rational design of clinical trials 
using antioxidants for NF1 vasculopathy.
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peripheral blood mononuclear cells
NF1
neurofibromatosis type 1
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reactive oxygen species
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Fig. 1. 
Neurofibromin regulates ROS production via p21Ras. WT (red), Nf1+/−(green), and Nf1−/− 
(blue) macrophage ROS production in response to phorbol myristate acid (PMA) in the 
presence or absence of p21Ras inhibitors. A and B. Data represent relative light units in 
response to PMA (A) and in response to PMA with the addition of superoxide dismutase (B) 
at indicated time point. C. Data represent fold change±S.E.M. (n=4) for WT (white bars) 
and Nf1+/− (black bars) macrophage maximal superoxide production in response to PMA 
(30 min) in the presence or absence of PD0325901 (10 nM) and wortmannin (50 nM). All 
comparisons are referred are in reference to unstimulated WT macrophages. *P<0.01 for 
WT versus Nf1+/− macrophages stimulated with PMA. **P<0.001 for WT and Nf1+/− 
macrophages stimulated with PMA versus WT and Nf1+/− macrophages stimulated with 
PMA in the presence of either PD0325901 or wortmannin.
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Fig. 2. 
Low dose H2O2 induces Nf1 +/− SMC proliferation and Erk activation. WT (white bars) and 
Nf1+/− (black bars) SMC proliferation in response to stimulation with indicated 
concentration of H2O2 (μM). A. Data represent genotype-specific fold change±SEM, n=4. 
*P<0.05 for Nf1+/− SMC versus Nf1+/− SMC stimulated with indicated concentration of 
H2O2. B. Data represent genotype-specific SMC viability±SEM (n=4) in the presence of 
H2O2. *P <0.01 for Nf1 +/− SMC versus Nf1 +/−SMC stimulated with indicated 
concentration of H2O2. C. Representative western blots of phospho-Erk, phospho-Akt, pro-
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caspase 3, cleaved caspase 3, and β-actin in WT and Nf1+/− SMC treated with indicated 
concentration of H2O2 (n =4).
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Fig. 3. 
Loss of neurofibromin enhances NOX2 expression in carotid arteries. Representative 
photomicrographs (A) and NOX2 expression (B) in control and injured carotid arteries from 
WT and Nf1+/− mice (n=3). A. Fluorescence indicating DHE staining in control and injured 
WT and Nf1+/− arterial cross sections. Scale bars: 400 μm. B. Representative western blot 
and quantitative densitometry for NOX2 and β-actin in pooled samples from WT Nf1+/− 
carotid arteries.
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Fig. 4. 
Genetic deletion of p47phox inhibits Nf1+/− neointima formation. Representative 
photomicrographs (A) and quantification of neointima area (B and C) of injured carotid 
arteries from WT, Nf1+/−, and Nf1+/−;p47phox−/− mice. A. Black arrows indicate neointima 
boundaries. Black boxes identify area of injured artery that is magnified below. Scale bars: 
100μm. B and C. Quantification of neointima area (B) and I/M ratio (C) of injured carotid 
arteries from WT, Nf1+/−, and Nf1+/−;p47phox−/− mice. Data represent mean neointima area 
or I/M ratio±SEM, n=8–11. *P<0.001 for WT and Nf1+/−;p47phox−/− mice versus Nf1+/− 
mice.
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Fig. 5. 
Lineage restricted deletion of gp91phox in myeloid cells inhibits Nf1+/− neointima formation. 
Representative photomicrographs (A) and quantification of neointima area (B and C) of 
injured carotid arteries from WT, Nf1flox/+;LysMcre, and Nf1flox/+;gp91flox/flox;LysMcre 
mice. A. Black arrows indicate neointima boundaries. Black boxes identify area of injured 
artery that is magnified below. Scale bars: 100 μm. B and C. Quantification of neointima 
area (B) and I/M ratio (C) of injured carotid arteries from WT, Nf1flox/+;LysMcre, and 
Nf1flox/+;gp91flox/flox;LysMcre mice. Data represent mean neointima area or I/M ratio±SEM, 
n=10–12. *P<0.001 for WT, and Nf1flox/+;gp91flox/flox;LysMcre mice versus 
Nf1flox/+;LysMcre.
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Fig. 6. 
Apocynin, a NOX2 inhibitor, reduces Nf1+/− neointima formation. Quantification of 
neointima area (A) and I/M ratio (B) of injured carotid arteries from WT and Nf1+/−mice 
treated with apocynin (100 mg/kg/day) or water. Data represent mean neointima area or I/M 
ratio ± SEM, n=8–10. *P<0.001 for WT versus Nf1+/− mice treated with water. **P<0.001 
for Nf1+/− mice treated with apocynin versus Nf1+/− mice treated with water. No statistical 
difference was observed between WT mice treated with apocynin and WT mice treated with 
water.
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Fig. 7. 
NF1 patients have evidence of chronic inflammation and oxidative stress. Quantification of 
total monocyte count (A), CD14+CD16+ + monocyte count (B), and peripheral blood MNC 
comet tail moment (C) in NF1 patients and age-, sex-matched controls. A. Data represent 
total monocyte count (cells/μL) for NF1 patients (n=13) and controls (n=18). P<0.01 for 
NF1 patients versus control patients. B. Data represent CD14+CD16+ + monocytes (cells/μL) 
for NF1 patients (n=13) and controls (n=17). C. Data represent CD14+ +CD16− monocytes 
(cells/μL) for NF1 patients (n=13) and controls (n=17). D. Data represent mean comet tail 
moment±S.D. for NF1 patients (n=10) versus controls (n=28). P<0.05 for NF1 versus 
control patients.
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